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Abstract
Primary signet ring cell carcinoma of urinary bladder is a rare type of bladder tumor and carries a
very high mortality rate. It may have a clinical presentation similar to common diseases like Benign
Prostatic Hypertrophy (BPH) and the management options are extremely limited. We report a
case of 58 year old Caucasian male who presented with a 5 month history of increased frequency
of urination, nocturia and weight loss without any fever or hematuria. He was found to have an
increased creatinine of 2.8 mg/dl and a prostate specific antigen level of 0.18 ng/ml. His azotemia
was thought to be secondary to BPH. A foley catheter was initially placed with a plan for outpatient
follow up. On removal of the catheter his problems persisted and he returned to the hospital.
Diagnostic work up including abdominal ultrasonography, computed tomography (CT) scan,
retrograde pyelogram, cystography and cystoscopic biopsies revealed the diagnosis of primary
signet ring cell carcinoma of urinary bladder. Although cystectomy was planned, our patient passed
away before this could be done.
Introduction
Primary signet ring cell carcinoma of urinary bladder is a
rare type of bladder tumor and carries a very high mortal-
ity rate. It may have a clinical presentation and symp-
tomatology similar to common diseases like Benign
Prostatic Hypertrophy (BPH). It is diagnosed with bladder
biopsy. Unfortunately, due to the rarity of this disease
entity and due to the aggressive nature of tumor, the treat-
ment options are extremely limited.
Case Presentation
A 58 year old previously healthy Caucasian male pre-
sented with a five month history of increased frequency of
urination, feeling of incomplete emptying and nocturia.
He denied any history of fever, hematuria, nausea, vomit-
ing or diarrhea. He complained of approximate 10 pound
weight loss over a period of 1 week. He reported a previ-
ous diagnosis of enlarged prostate with a normal Prostate
Specific Antigen (PSA). He also reported a recent history
of "small heart attack" for which he was medically treated
at an outlying facility where he was also informed about
poor kidney function. He also gave history of recently
diagnosed hypertension and a 80 pack year of ongoing
smoking. His medications included amlodipine, finas-
teride, doxazosin, metoprolol, clopidrogel, aspirin and
lovastatin. All of these were started 5 days prior to presen-
tation. Physical examination revealed a healthy appearing
male with normal vital signs. His rectal exam revealed a
slightly enlarged, non-tender prostate. Rest of the physical
exam was unremarkable. Laboratory data revealed hemo-
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globin 10.3 g/dl, blood urea nitrogen 24 mg/dl, creatinine
2.7 mg/dl, and PSA level 0.18 ng/ml. Urinalysis was neg-
ative for RBC's, WBC's, bacteria, or nitrates. Retroperito-
neal ultrasound showed normal sized kidneys with mild
pyelocaliectasis bilaterally, prostate measured 4 × 2.7 ×
2.6 cm with homogenous echotexture, otherwise unre-
markable. Immediately after placement of foley catheter
he had 650 ml of urine output. Blood urea nitrogen
decreased to 18 mg/dl and serum creatinine decreased to
1.7 mg/dl. His azotemia was thought to be secondary to
BPH and he was discharged with indwelling foley catheter
to be followed up as an outpatient. At outpatient clinic,
on removal of his foley catheter, his post void residual was
found to be 150 ml. Various management options includ-
ing surgical interventions were discussed with the patient
in detail. After discussion patient was discharged home to
be followed up as an outpatient but was started on tamsu-
losin. He returned to the hospital with complaints of
urgency and frequency. His creatinine had increased to
5.0 mg/dl. Abdominal CT at this time revealed bilateral
hydronephrosis and hydroureter (Figure 1 and 2). This
finding was confirmed on retrograde pyelogram. Cystog-
raphy showed marked thickening of the urinary bladder
trabeculae (Figure 3). Cystoscopy revealed the entire blad-
der mucosa to be thickened and edematous with an exag-
gerated granular type appearance and bilateral uretero-
vesical junction stenosis prompting placement of bilateral
ureteral stents. He subsequently had a diuresis producing
6 liters of urine. This was followed by a reduction in the
serum creatinine from 5.2 to 3.1 mg/dl over two days.
Pathological analysis of tissue from random bladder wall
biopsies at the time of cystoscopy revealed an infiltrate of
cells beneath the surface epithelium (Figure 4). These cells
were described as small, with a high nuclear-cytoplasmic
ratio. Many cells showed a cytoplasmic vacuolization with
displacement of crescentic, hyperchromatic nuclei (Figure
5). Special stain results were positive for mucin (Figure 6),
pan-cytokeratin, CK7 and CK20 but negative for PSA and
PAP (prostatic acid phosphatase). Based on these results,
a diagnosis of Primary Signet Ring Cell Carcinoma
(PSRCC) of the bladder was established. He underwent
esophagogastroduodenoscopy and colonoscopy to evalu-
ate possible primary site of his malignancy but were found
to be negative. Management plans were then made for
radical cystectomy. But the subsequent course was com-
plicated by colitis secondary to Clostridium difficile
requiring total colectomy with diverting ileostomy. Path-
Computerized tomography scan showing bilateral hydrone- phrosis and hydroureter Figure 1
Computerized tomography scan showing bilateral 
hydronephrosis and hydroureter.
 
Computerized tomography scan showing urinary bladder  wall thickening Figure 2
Computerized tomography scan showing urinary 
bladder wall thickening.
 
Cystogram showing marked trabecular thickening Figure 3
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ologic evaluation of the removed colon showed no evi-
dence of malignant involvement. Recovery was further
complicated by myocardial infarction requiring coronary
artery bypass grafting. The patient failed to recover and
continued to deteriorate. After discussion with family his
care was transferred to hospice and he passed away. Cys-
tectomy was therefore not performed.
Discussion
Primary signet-ring cell carcinoma (PSRCC) is a rare vari-
ation of adenocarcinoma of the urinary bladder. English
literature review on pubmed reveals less than 100 cases
reported. Adenocarcinoma constitutes 2% of all bladder
cancers with the majority being metastatic rather than pri-
mary[1]. A study of 713 cases of primary bladder tumor in
Sweden revealed 4 signet ring cell carcinomas, only 0.6%
[2]. Another series of 715 bladder cancers in Germany
revealed 18 adenocarcinomas but only one with the clas-
sic histologic pattern of signet-ring cell carcinoma [3]. Sig-
net-ring cells are much more commonly described in
primary adenocarcinoma of the stomach, colon, breast or
gallbladder and malignancies of these organs should be
excluded before diagnosing PSRCC of urinary bladder [3].
A 3:1 male to female predominance has been shown [4],
but in male patients, it is especially necessary to rule out
prostatic adenocarcinoma as a possible site of origin [5].
Most patients present in middle-age with symptoms indis-
tinguishable from the much more common transitional
cell carcinoma of the bladder. The most common present-
ing symptoms are hematuria and difficulty in urination
which can be mistaken for a urinary tract infection. In
cases of rapid growth in the trigone area, oliguria, bladder
irritation, and renal failure can be the initial presenting
signs [6]. Yamamoto and associates described one patient,
similar to our own, who presented with renal failure and
oliguria without gross hematuria [7]. Cases have also been
reported presenting with a palpable suprapubic mass [8]
and one with a palpable supraclavicular lymph node [4].
The average time from initial symptoms to the first physi-
cian visit has been reported to be five months, [8] but no
relationship between the duration of symptoms before
presentation and the stage of disease has been found[5].
Grignon et al compared the gross features of 34 cases of
primary signet-ring cell carcinoma. They found that
47.1% have no mucosal or mass lesion present on cystos-
copy. The most common description is of "edematous
mucosa" but descriptions of erythematous or finely gran-
ular mucosa are also found. As in our case, the bladder
Bladder biopsy slide showing normal transitional epithelium  on the left and infiltrative tumor cells on the right Figure 4
Bladder biopsy slide showing normal transitional epi-
thelium on the left and infiltrative tumor cells on the 
right.
 
Normal bladder 
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Infiltrative tumor 
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High power field of bladder biopsy showing tumor cells,  many with signet ring appearance Figure 5
High power field of bladder biopsy showing tumor 
cells, many with signet ring appearance.
 
Signet ring cell 
Mucicarmine stain showing mucin vacuoles in signet ring cells Figure 6
Mucicarmine stain showing mucin vacuoles in signet 
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wall is often described as thickened or fibrotic [4]. Signet-
ring cells first invade the mucosa and submucosa of a hol-
low organ with eventual full-thickness involvement. This
pattern of invasion can produce extensive lateral spread
without the development of a protruding neoplasm, [9]
but in more than half of cases, a definite mass lesion is
found with morphology ranging from polypoid or pedun-
culated to sessile to ulcero-infiltrative [4]. Often a pyelo-
gram will show a filling defect or the CT scan may show
diffuse bladder wall thickening [1]. Because this tumor
mainly has an infiltrative rather than exophytic growth
pattern, it is not readily identifiable on cystoscopy. A full-
thickness biopsy of the bladder may be necessary to make
the diagnosis [8]. As in our patient, this diffusely infiltrat-
ing lesion can occlude the ureters early in its course caus-
ing obstruction and hydronephrosis [9].
Signet ring cells are described as crescent shaped cells con-
taining nuclei compressed to one edge of the cell by large
amounts of cytoplasmic mucin appearing as a single clear
vacuole in some tumors and as a foamy, multivesicular
cytoplasmic material in others [4,8]. Mucin accumula-
tions form in the cytoplasm and nuclei are unevenly dis-
tributed [7]. Routine mucin staining of otherwise normal
transitional cell carcinoma will reveal signet ring cells in
many cases and the exact percentage of signet ring cells
that must be present in order to make the diagnosis of
PSRCC of the bladder has not been established. Holmang
and associates suggested that 50-60% of the tumor should
be made up of signet-ring cells to make this classification
[2]. However, because the linitis plastica-like pattern of
diffuse signet-ring cell infiltration is associated with a
poorer prognosis, it has been suggested that only this pat-
tern should be considered a pure signet-ring cell carci-
noma [4]. Bladder tumors found to consist solely of
signet-ring cells should prompt a thorough search for a
distant primary site. Those consisting of a mix of signet-
ring cells and transitional cells are more likely to be of pri-
mary bladder origin [1]. Also, PSRCC is usually a solitary
lesion (63%) in contrast to transitional cell carcinoma
which is most often multifocal (66%) [8].
Three theories for the histogenesis of this type of carci-
noma have been suggested in literature. First is the meta-
plastic potential of urothelium which may occur along the
surface of the bladder or in areas of cystitis cystica within
the bladder. The second is that diffuse signet ring cell ade-
nocarcinoma derives from isolated signet ring cells that
exist scattered in normal transitional epithelium. The
third possibility is that of signet ring cell carcinoma aris-
ing from metaplastic transitional cell carcinoma [4,10-
14].
Treatment options for PSRCC are limited. This is a rare
disease entity; no specific chemotherapy has been recom-
mended in the literature. Radiotherapy has also not been
shown to be successful [2]. Total cystectomy with excision
of adjacent tissues may offer some hope in this aggressive
malignancy [8]. There is no specific serum tumor marker
for PSRCC of the bladder, but elevated carcinoembryonic
antigen (CEA) levels have been reported. In cases where
CEA is elevated at diagnosis, levels may be used for post-
operative monitoring [7]. Death is most often the result of
distant metastases. Therefore, the most successfully
reported treatment strategy is resection of the primary
tumor before metastasis occurs [1]. As extensive intramu-
ral growth is so often found at diagnosis, total cystectomy
may be the only hope for cure [15]. Kondo and associates
reported no difference in mean remission rates between
patients who received radiotherapy either pre- or post-
operatively and those who did not [8]. In 2001, Yasuhiro
and associates described successful treatment of a PSRCC
of the bladder with intra-arterial administration of carbo-
platin through the left vesicular artery. Complete remis-
sion had been maintained for 44 months at the time of
their publication [16]. Unfortunately, this is the only such
case reported. This disease typically carries a poor progno-
sis, often due to extensive spread at the time of diagnosis.
Conclusion
PSRCC of urinary bladder is a rare entity with a very poor
prognosis. Since patients may present with clinical picture
similar to common diseases like BPH it may be difficult to
diagnose early in the course of the disease. Treatment
options are extremely limited and not well studied. There-
fore it is important for the clinicians to be aware of this
disease entity.
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